Update Interview with New CEO Brent Charleton Reveals Significant Potential for EnWave Corp
We’re very pleased to have Mr. Brent Charleton with us today, the brand new President and CEO of EnWave Corporation (TSXV:ENW – $1.24 CAD & OTC:NWVCF – $0.95 USD & Frankfurt:E4U – €0.81), to give us an update on his Company.
Mr. Charleton first discusses the departure of Dr. Durance as CEO last month and thoroughly explains what happens with the Company’s patents now that Dr. Durance is no longer with the Company.
In addition, Mr. Charleton delivers plenty of valuable information about EnWave’s pharmaceutical business. He talks about what went wrong with Sutro Biopharma, the excellent recent news from Merck, and how the potential collaboration with GEA could be a big win for both companies.
The interview also digs deeper into the Company’s developments in the flourishing cannabis industry. The CEO gives an overview of the current deals and negotiations with Tilray and other Canadian Licensed Producers. In addition, he provides more details about other cannabis agreements in the pipeline.
Moreover, a substantial portion of the interview is devoted to NutraDried and its Moon Cheese sales. Investors find out about the market potential for the crunchy cheese snack and new product development at the subsidiary.
Investors also find out more about the partnership with Bonduelle, and the extremely exciting opportunity with the US Army Natick Soldier R&D Center.
Access our interview by clicking the play button on the media player below,
or download our convenient transcript.
|Smallcaps.us Advice: Buy||Price Target: $3.88||Latest Company Report (pdf)|
|For important disclosures, please read our disclaimer.|